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robust. CONCLUSIONS: In the treatment of schizophrenia, quetiapine XR dominates 
quetiapine IR due to lower cost, reduced relapse and hospitalization rate and domi-
nates paliperidone due to lower cost. REFERENCE: Edwards NC et al. Pharmaco-
economics 2005;23(Suppl. 1):75–89.
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OBJECTIVES: To analyse effectiveness of ﬂupentixol compared to other ﬁrst and 
second generation antipsychotics for the treatment of schizophrenia in routine care. 
METHODS: A retrospective cohort study was conducted using administrative data 
from four sickness funds with a combined number of 12.6 million insured. Patients 
discharged from hospital with an ICD-10 diagnosis of schizophrenia in 2003 were 
followed for 12 months. Rehospitalisation during follow-up was analysed using a 
hurdle regression model. Differences in treatment costs, deﬁned as cost of pharmaceu-
tical and cost of inpatient care, were analysed assuming a gamma distribution for 
treatment costs and using a log-link-function. To control for possible confounding, 
the models adjusted for age, gender, and prior hospitalisations due to schizophrenia 
in 2000, 2001 and 2002. RESULTS: A total of 8610 insured were included, of which 
177 treated with ﬂupentixol during follow-up, while 429 and 2284 were treated with 
other ﬁrst and second generation antipsychotics, respectively. Compared to patients 
treated with ﬂupentixol (predicted hospitalisation for the average patient: 19 days), 
predicted hospitalisation did not differ signiﬁcantly for patients treated with other ﬁrst 
(16.9 days, p  0.0919) or second generation antipsychotics (19.5 days, p  0.1418). 
Predicted treatment costs for the average patient (age  41.5 years, male, prior hospi-
talisation 26.7 days per year) were a4384 if treated with ﬂupentixol, a7021 if treated 
with an other ﬁrst generation antipsychotic, and a6819 if treated with a second genera-
tion antipsychotic. Differences in treatment costs between ﬁrst and second generation 
antipsychotics increased with severity. CONCLUSIONS: The effectiveness of ﬂupen-
tixol preventing relapse in patients with schizophrenia appears to be similar to that 
of other ﬁrst and second generation antipsychotics. However, the low treatment costs 
for patients treated with ﬂupentixol might be explained by the small number of 
patients who were hospitalised (70 insured) and the larger share of patients treated 
with its depot formulation.
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OBJECTIVES: A cost-utility analysis of a new antidepressant agomelatine (Valdoxan) 
compared to generic venlafaxine and placebo in the treatment of MDD was performed 
from the Finnish societal perspective. METHODS: The analysis is based on a Markov 
state transition model with second-order Monte Carlo simulation and two year time-
frame. Conservatively, agomelatine and venlafaxine were assumed to be equally effec-
tive in the treatment of depressive symptoms, but to differ in costs, side effect proﬁles, 
clinically signiﬁcant sleep disorders during treatment, discontinuation rates and dis-
continuation symptoms based on agomelatine clinical trials. Finnish EQ-5D utilities, 
health care resource use, travelling and production losses (derived from the actual 
work rates of MDD patients using human capital approach) were estimated based on 
a Finnish study including 298 patients with MDD, adjusted for confounders (age, 
gender, marital status, income and education), and matched to model states and 
adverse events using two-stage multivariate models. The costs were presented in 2008 
value. Annual discounting rate considered was 3%. RESULTS: Compared to generic 
venlafaxine and placebo the treatment with agomelatine resulted in 0.012 and 0.066 
additional quality-adjusted life-years (QALY) gained, and in 356 and a126 additional 
treatment costs during the two year time-frame, respectively. The corresponding 
additional costs including production losses were 220 and a3255. Agomelatine was 
associated with an incremental treatment cost of a29,000/QALY gained compared to 
generic venlafaxine. When production losses were included, this ratio fell to a18,000/
QALY gained. According to cost-effectiveness acceptability frontier (excl. production 
losses), the probability of agomelatine’s cost-effectiveness was 57 and 90% with the 
willingness-to-pay levels of a30,000 and a50,000 per QALY gained, respectively. 
Agomelatine dominated placebo. One-way sensitivity analyses showed that the results 
were robust to key parameter changes. CONCLUSIONS: Agomelatine is a cost-
 effective treatment for MDD versus generic venlafaxine and dominant versus placebo 
based on the representative Finnish data.
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OBJECTIVES: Little or no information exist on the cost of mental health services in 
Africa, even though mental health disorders represent a major public health concern 
in the region, in terms of health and economic impact. The study estimated the total 
and average/unit costs of psychiatric hospital services (including inpatients and out-
patients services) to guide policy and psychiatric hospital management efﬁciency in 
Nigeria. METHODS: The study was exploratory and analytical, examining 2008 data. 
Using standardized costing methodology based on ingredient approach, top-down 
methodology was combined with step-down approach to allocate resources (overhead 
and indirect costs) to the ﬁnal cost centers. All costs associated with treatment of the 
psychiatric patients (including annualised costs of capital items) were measured on 
aggregate basis as well as on per capita basis. Costs were calculated from the perspec-
tive of the health care facility, and converted to US Dollars at the 2008 exchange rate. 
RESULTS: Personnel costs average over 75% in all departments. Unit cost of outpa-
tient visit is similar to the cost of inpatient day averaging $50, while cost per inpatient 
admission is about $3288. Cost of emergency consultation is about two times the cost 
of an outpatient visit or inpatient day. About 65 new outpatients could be treated 
for the cost of one inpatient admission. Levels of subsidization for inpatients are 
over 90% while ancillary services are not subsidized hence full cost recovery. Cost of 
drugs is about 4.4% of the total costs and each prescription averaged $7.48. 
CONCLUSIONS: The unit cost estimates fall within the European estimates for 
 psychiatric health services and WHO-CHOICE’s ‘high estimates’ for tertiary health 
facilities in SSA. Adequate research is needed to determine the cost of providing 
 psychiatric hospital services in Africa to inform effective policy and improved man-
agement efﬁciency for mental health services in the region.
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OBJECTIVES: Clinical efﬁcacy and symptom control are the primary basis for atypical 
antipsychotic (AAP) selection. Clinical effectiveness outcomes are less well studied as 
treatment considerations. Retrospective administrative-claims data analyses for patients 
with schizophrenia and bipolar disorder were completed to characterize the association 
between AP treatment and clinical and economic patient outcomes. METHODS: 
Patients with schizophrenia (n  2737) or bipolar disorder (n  9707) on AAP (aripip-
razole, olanzapine, risperidone, quetiapine or ziprasidone) treatment were identiﬁed in 
the 2004–2005 PharMetrics Patient-Centric Database. Patients with q12 months con-
tinuous enrollment before and after their earliest AAP claim were included in the analy-
ses and stratiﬁed by their most-recent AAP claim. Treatment cohorts were propensity 
score matched. Index treatment differences were characterized by multivariable regres-
sion models. Time to discontinuation (Cox proportional hazard regression), psychiatric 
admission probability (logistic regression) and expenditures (GLM) were evaluated. 
Post–index period costs were tallied. RESULTS: Schizophrenia patient cohorts 
were aripiprazole (n  367), olanzapine (n  755), risperidone (n  1004), quetiapine 
(n  404) and ziprasidone (n  207). Mean age range was 40–44 years. After propensity 
score matching, there were no signiﬁcant differences across cohorts in time to discon-
tinuation and psychiatric hospitalization probability. Total quetiapine expenditures 
were greater than ziprasidone ($16,417 vs. $12,547; p  0.0024). CONCLUSIONS: 
Limited statistical differences were observed in this population. Further research should 
be conducted to understand whether such differences occur in other large databases 
and their clinical and economic relevance for AAP patient populations.
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OBJECTIVES: To evaluate the cost-effectiveness of quetiapine extended release 
300 mg once daily (o.d.) in adult patients with acute bipolar depression compared 
with average standard adult doses of paroxetine 20 mg o.d. and lithium 1.2 g o.d. 
METHODS: A weekly cycle 7-state markov model was designed to evaluate the cost-
effectiveness of quetiapine extended release over a 3-year time horizon from the per-
spective of the UK National Health Service. Remission, treatment-emergent mania, 
discontinuations, signiﬁcant weight-gain (q7%) and extrapyramidal adverse event rate 
probabilities were used in the model. These, in the form of relative risks, were obtained 
from two separate indirect comparisons of quetiapine extended release versus parox-
etine and lithium with placebo as the common comparator. These comparisons were 
obtained from randomised blinded studies in the AstraZeneca trial registry for que-
tiapine in the treatment of acute bipolar depression. A systematic literature review was 
completed to identify suitable health state utility values. Costs included pharmacologi-
cal therapy and resource use associated with the treatment of mood events. Results 
were reported in cost (2009 values) per quality-adjusted life years (QALYs). A proba-
bilistic sensitivity analysis (PSA) was conducted to assess the robustness of the results. 
RESULTS: Quetiapine extended release was a cost-effective treatment option for 
adults with acute bipolar depression versus both paroxetine and lithium. The deter-
ministic incremental cost-effectiveness ratios were £1,541/QALY and £14,548/QALY, 
when quetiapine extended release was compared with paroxetine and lithium, respec-
tively. These results were supported in the probabilistic sensitivity analysis. Eighty-four 
percent and 92% of simulations found quetiapine extended release to be cost-effective 
at a threshold of £30,000/QALY versus paroxetine and lithium, respectively. 
 CONCLUSIONS: The results of this cost-utility analysis suggest that not only is 
